Kinase News and Research

RSS

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics.

22 Jan 2016

BCR–ABL transcript type linked to TKI response, outcomes

The type of BCR–ABL transcript could have an impact on tyrosine kinase inhibitor choice in patients with chronic myeloid leukaemia , according to research published in Blood.

22 Jan 2016

UT Southwestern researchers reveal how CDK4/6-inhibitors alter pancreatic cancer cell metabolism

UT Southwestern Medical Center researchers have found that cancer drugs known as CDK4/6-inhibitors alter the metabolism of pancreatic cancer cells, revealing a biologic vulnerability that could be exploited for therapeutic gain.

22 Jan 2016

Researchers identify biomarkers that may influence potential new drug design or alternative treatments of cancer

Researchers have discovered gene-targets (biomarkers) that may enable alternative treatments or the potential design of new drugs that target metastasis-promoting tumor genes.

22 Jan 2016

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

In results published on October 19, 2015 in the Journal of Lipid Research, a team of translational scientists at the Medical University of South Carolina report a new reason why non-alcoholic steatohepatitis (NASH) worsens in people who are obese.

20 Jan 2016

MD Anderson-led study explores role of HIF-1 in triple-negative breast cancer

A multi-institutional international study led by scientists at The University of Texas MD Anderson Cancer Center has revealed new information about how molecules called long non-coding RNAs (lncRNA) interact with HIF-1, a signaling pathway that is overexpressed in many cancers. HIF-1 has been shown to regulate breast cancer progression.

12 Jan 2016

Researchers reveal specific enzyme responsible for sensing energy source that fuels growth of cancer cells

An international research team formed by a University of Cincinnati cancer researcher has shown for the first time that a specific enzyme is responsible for sensing the available supply of GTP, an energy source that fuels the uncontrolled growth of cancer cells. The research underscores the enzyme's potential to become a therapeutic target for future cancer drugs.

11 Jan 2016

Sugary foods may affect recovery from heart attack

Scientists at the University of Leicester have demonstrated for the first time the mechanism by which the level of sugar in your blood can affect the contraction of blood vessels, with potentially dangerous effects on the heart and blood pressure.

8 Jan 2016

Pediatric oncologists devise new treatments for neuroblastoma

Pediatric oncologists from The Children's Hospital of Philadelphia have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma.

7 Jan 2016

Combining NELL-1 with BMP2 therapy may promote bone development

Bone morphogenetic protein-2 (BMP2) is used clinically to promote bone repair. However, the high BMP2 concentrations required to stimulate bone growth in humans may produce life-threatening adverse effects such as cervical swelling in spinal fusion procedures, a problem that prompted an FDA warning in 2008.

7 Jan 2016

Researchers identify mechanism that allows cancer cells to grow rapidly when blood sugar levels rise

Researchers have identified a mechanism that allows cancer cells to respond and grow rapidly when levels of sugar in the blood rise. This may help to explain why people who develop conditions in which they have chronically high sugar levels in their blood, such as obesity, also have an increased risk of developing certain types of cancer.

6 Jan 2016

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).

5 Jan 2016

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Xcovery, a developer of targeted therapeutics for ALK+ non-small cell lung cancer (NSCLC) is scheduled to present January 6th, 2016 at the fourth annual AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, at the Hard Rock Hotel, in San Diego, CA.

5 Jan 2016

Researchers discover methods for reducing age-related stem cell dysfunction, metabolic disease in aged mice

Mayo Clinic researchers have taken what they hope will be the first step toward preventing and reversing age-related stem cell dysfunction and metabolic disease. That includes diabetes, which affects 12.2 million Americans age 60 and older, according to the National Council on Aging.

5 Jan 2016

IASLC lauds FDA approval of alectinib for lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients in their battle against the disease.

24 Dec 2015

Researchers identify underlying molecular mechanism of cardiac hypertrophy

Specific genes are responsible for determining cell growth and differentiation during the early stages of cardiac development. Reactivation of these genes later in life can lead to an abnormal thickening of the heart muscle. Researchers from Charité -- Universitätsmedizin Berlin lead by Professor Silke Rickert-Sperling have been able to identify the underlying molecular mechanism.

23 Dec 2015

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Oncology & Hematology Review, the peer-reviewed journal, has published a review highlighting recent data around rociletinib, an investigational therapy in patients with previously treated EGFR mutant-positive non-small cell lung cancer.

23 Dec 2015

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.

22 Dec 2015

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib than gefitinib as first-line treatment, researchers report at the first ESMO Asia 2015 Congress in Singapore.

21 Dec 2015

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati Therapeutics, Inc. today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265.

21 Dec 2015

Kinase News and Research

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

BCR–ABL transcript type linked to TKI response, outcomes

UT Southwestern researchers reveal how CDK4/6-inhibitors alter pancreatic cancer cell metabolism

Researchers identify biomarkers that may influence potential new drug design or alternative treatments of cancer

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

MD Anderson-led study explores role of HIF-1 in triple-negative breast cancer

Researchers reveal specific enzyme responsible for sensing energy source that fuels growth of cancer cells

Sugary foods may affect recovery from heart attack

Pediatric oncologists devise new treatments for neuroblastoma

Combining NELL-1 with BMP2 therapy may promote bone development

Researchers identify mechanism that allows cancer cells to grow rapidly when blood sugar levels rise

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Researchers discover methods for reducing age-related stem cell dysfunction, metabolic disease in aged mice

IASLC lauds FDA approval of alectinib for lung cancer treatment

Researchers identify underlying molecular mechanism of cardiac hypertrophy

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News